Afuco™ Anti-CD44 ADCC Therapeutic Antibody (Bivatuzumab), ADCC Enhanced

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD44. Bivatuzumab is a humanized monoclonal antibody against CD44 v6.
Supplier Creative Biolabs
Product # AFC-TAB-727
Pricing Inquiry
Host Human
Target CD44
Species Reactivity Human
Type ADCC enhanced antibody
Applications ELISA, FC, IP, FuncS, IF, Neut
Storage Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Feedback